Associated Genetic Biomarkers
NCI Definition: A rapidly growing malignant mesenchymal neoplasm. It is characterized by the presence of round cells with myoblastic differentiation and a fibrovascular stroma resembling an alveolar growth pattern. The tumor usually presents in the extremities. 
Alveolar rhabdomyosarcomas most frequently harbor alterations in FOXO1, PAX3, MYCN, PAX7, and MYCL .
FOXO1 Fusion, PAX3-FOXO1 Fusion, FOXO1-PAX3 Fusion, MYCN Amplification, and PAX7-FOXO1 Fusion are the most common alterations in alveolar rhabdomyosarcoma .
There are 5 clinical trials for alveolar rhabdomyosarcoma, of which 4 are open and 1 is completed or closed. Of the trials that contain alveolar rhabdomyosarcoma as an inclusion criterion, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open).
MYCN, PD-L1, and TMB-High are the most frequent gene inclusion criteria for alveolar rhabdomyosarcoma clinical trials .
Tb-403, cyclophosphamide, and dactinomycin are the most common interventions in alveolar rhabdomyosarcoma clinical trials.
Significant Genes in Alveolar Rhabdomyosarcoma
MYCN is altered in 15.0% of alveolar rhabdomyosarcoma patients .
MYCN is an inclusion eligibility criterion in 1 clinical trial for alveolar rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and alveolar rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.